Precision Medicine in Ovarian Cancer: Understanding the Evolving Role of PARP Inhibitors

Explore recent improvements in the use of PARP inhibitors to treat ovarian cancer with this IME-certified program featuring an on-demand Webcast and downloadable slides.

This educational program is intended for clinicians practicing medicine outside of the United States.

Share

Program Content

Activities

OC: 1st-Line Maintenance Niraparib
My Perspective on the Recent Approval of Niraparib as First-line Maintenance Therapy in Ovarian Cancer and the Clinical Implications
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 11, 2021

Expires: January 10, 2022

Activities

PARPi in ND Ovarian Cancer
Role of PARP Inhibitor Maintenance Therapy in Newly Diagnosed Ovarian Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2020

Expires: December 16, 2021

PARPi in Recurrent OC
PARP Inhibitors in Recurrent Ovarian Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 22, 2020

Expires: December 21, 2021

OC: Which PARPi to Use
How to decide when to use different PARPi
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 22, 2020

Expires: December 21, 2021

Activities

PARPi in Ovarian Cancer
Precision Medicine in Ovarian Cancer: Understanding the Evolving Role of PARP Inhibitors
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: February 11, 2021

Expires: February 10, 2022

Faculty

cover img faculity

Antonio Gonzalez-Martin, MD, PhD

Head, Medical Oncology
Co-Director, Oncology Department
Oncology Department, Medical Oncology Service
Clinica Universidad Navarra
Madrid, Spain

cover img faculity

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline